Products from BPS Bioscience require a minimum order value above 400€
Encompassing Amino Acids: 2-396(end)
Application: Useful for the study of enzyme kinetics, screening inhibitors, and selectivity profiling.
Background: VRK1 (vaccinia-related kinase), is a member of the serine/threonine kinase family. It is found predominantly in dividing tissues, such as testis and thymus. It is a nuclear protein involved in gene regulation, DNA damage response, and cell proliferation through phosphorylation of histones, p53, and other transcription factors. Its roles in cell proliferation and DNA repair make it relevant for cancer survival and progression, and high levels of VRK1 have been found in breast and colon cancer, lung cancer, and gliomas. A reduction in VRK1 activity can thus provide benefits, and the combined use of VRK1 inhibitors and PARP inhibitors, such as an Olaparib, has been shown to contribute to synthetic lethality. The use of VRK1 inhibitors, alone or in combination therapy, may prove highly beneficial in cancer therapy.
Description: Recombinant human full-length serine/threonine kinase VRK1 (vaccinia-related kinase), amino acids 2-396(end). This construct contains an N-terminal GST-tag followed by a thrombin cleavage site. The protein was affinity purified.
Format: Aqueous buffer solution.
Formulation: 40 mM Tris-HCl pH 8.0, 110 mM NaCl, 2.2 mM KCl, 20% glycerol, and 3 mM DTT
Genbank: NM_003384
Purity: ≥90%
Storage Stability: -80°C
Supplied As: At least 6 months at -80°C.
Tags: VRK serine/threonine kinase 1, VRK1, VRK-1, PCH1, PCH1A, HMNR10, Vaccinia-related kinase 1,
Target: GST-Tag
Uniprot: Q99986
Warnings: Avoid freeze/thaw cycles
Biosafety Level: Not applicable (BSL-1)
Deutsch
English
